Oni, Louise;
Platt, Caroline;
Marlais, Matko;
McCann, Liza;
Barakat, Farah;
Hesseling, Markus;
Cottis, Hannah;
... Dudley, Jan; + view all
(2025)
National recommendations for the management of children and young people with IgA vasculitis: a best available evidence, group agreement-based approach.
Archives of Disease in Childhood
, 110
(1)
pp. 67-76.
10.1136/archdischild-2024-327364.
Preview |
Text
National recommendations for the management of children and young people with IgA vasculitis a best available evidence, grou.pdf - Published Version Download (704kB) | Preview |
Abstract
Objective: IgA vasculitis (IgAV) is the most frequently experienced subtype of vasculitis seen in children. Most children fully recover, however, complications including chronic kidney disease are recognised. The aim of this project was to use a best available evidence, group agreement, based approach to develop national recommendations for the initial management of IgAV and its associated complications. // Methods: A fully representative multiprofessional guideline development group (GDG), consisting of 28 members, was formed and met monthly. Graded recommendations were generated using nationally accredited methods, which included a predefined scope, open consultation, systematic literature review, evidence appraisal, review of national or international guidelines and a period of open consultation. Audit measures and research priorities were incorporated. // Results: The IgAV GDG met over a 14-month period. A total of 82 papers were relevant for evidence synthesis. For the initial management, four topic areas were identified with five key questions generating six graded recommendations related to classification, specialist referral and musculoskeletal involvement. For the associated complications, five topic areas with 12 key questions generated 15 graded recommendations covering nephritis, gastrointestinal and testicular involvement, atypical disease and follow-up. Open consultation feedback was incorporated. The guidelines were endorsed by the UK Kidney Association and Royal College of Paediatrics and Child Health and are available online. // Conclusion: Despite IgAV being a rare disease with limited evidence, a national standardised approach to the clinical management for children and young people has been achieved. This should unite approaches to care and act as a foundation for improvement.
Archive Staff Only
 |
View Item |
